After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug
Executive Summary
Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.
You may also be interested in...
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.
Gilead Avoids $2.5bn Jury Verdict As Judge Rules Merck's Hep C Patent Is Invalid
Merck to appeal decision after district court says Gilead's discovery of sofosbuvir was 'neither routine nor simple.'
Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW
The latest drug development news and highlights from our US FDA Performance Tracker.